

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ritamix Global Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1936)

VOLUNTARY BUSINESS UPDATE IN RELATION TO RESEARCH AND DEVELOPMENT OF HEALTH SUPPLEMENT PRODUCTS

The board (the “**Board**”) of directors (the “**Directors**”) of Ritamix Global Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that one of its wholly-owned subsidiaries, Kevon Sdn. Bhd. (“**Kevon**”), which engages in distribution of human food ingredients, is venturing into the research and development, formulation, sale and distribution of Nicotinamide Mononucleotide (“**NMN**”) dietary supplements, which are also known as anti-aging health supplement products.

The Company entered into a collaboration agreement with Bioalpha International Sdn. Bhd. (“**BISB**”), a wholly-owned subsidiary of Bioalpha Holdings Berhad (“**Bioalpha**”), a company listed on Bursa Malaysia Berhad (Stock Code: 0179), for BISB to manufacture and supply NMN dietary supplements for the People’s Republic of China and Southeast Asia (including Malaysia) markets. Bioalpha and the Group will also cooperate with Universiti Teknologi Malaysia to conduct research on health supplement products based on NMN.

The Board considers that it has been one of the business strategies of the Company to consider promising business and investment opportunities from time to time in order to increase the overall value of the Group for the benefit of the shareholders of the Company (the “**Shareholders**”). The Board expects the Group to benefit from the combination of its experience in research and development, formulation, sales and marketing together with Bioalpha’s manufacturing background of anti-aging drugs and healthcare products.

The Board believes that the collaboration will further enrich the product portfolio of the Group in health supplement products, and is in the best interest of the Company and the Shareholders as a whole.

The first in-house product of the Group, an NAD+ (as defined below) booster supplement in powder sachet form, also known as “Tang Yuan Tang”, is expected to reach the Malaysian market in early 2021.

In the event that there is any material progress of the plan to research and develop the aforementioned health supplement products, the Company will make further announcement(s) in compliance with the Rules Governing the Listing of Securities on the Stock Exchange as and when appropriate.

About NMN

NMN is a precursor, or rather, the ingredient to make nicotinamide adenine dinucleotide (“**NAD+**”), which is a critical coenzyme found in human cells, to carry out cellular processes such as glucose metabolism. Studies have found that when an organism ages, the level of NAD+ decreases, which slows down many biological functions. The main reason for consuming NMN dietary supplements, which are mainly marketed in capsule or powder form, is to increase the level of NAD+ in human bodies.

About Bioalpha

Bioalpha is an integrated health supplement company listed on Bursa Malaysia Berhad (Stock Code: 0179). It principally engages in agricultural development, research and development, manufacturing, distribution and marketing of functional food and health supplement products under original design manufacturer and original brand manufacturer basis, as well as operating a retail pharmacy chain under the brand “Constant”.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
Ritamix Global Limited
Dato’ Sri Lee Haw Yih
Chairman and Executive Director

Malaysia, 8 December 2020

As at the date of this announcement, the executive Directors are Dato’ Sri Lee Haw Yih and Datin Sri Yaw Sook Kean; the non-executive Director is Mr. Lee Haw Shyang; and the independent non-executive Directors are Ms. Ng Siok Hui, Mr. Lim Chee Hoong and Mr. Lim Heng Choon.